Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
In a highly anticipated head-to-head trial of Eli Lillys Zepbound (tirzepatide) and Novo Nordisks Wegovy (semaglutide), Zepbound has come out on top as it helped trial participants lose significantly more weight than Wegovy over an 18-month period
(Source: iPharma Pharmacy, 2026) A 2026 systematic review and meta-analysis (Prospero CRD42024535096) searched Cochrane Library, EMBASE, and Medline through September 2024, identifying 9,654 studies and including 11 randomized controlled trials comparing GLP-1 receptor agonists against no treatment, placebo, lifestyle intervention, oral contraceptives, anti-androgens, or metformin in PCOS patients
Insurance coverage varies widely, and many plans dont cover weight loss medications or require extensive prior authorization
Wegovy is FDA-approved to: Manage weight in adults and children ages 12+ with obesity (BMI of 30+) and in adults with overweight with at least one weight-related medical condition (e.g
Participants in the STEP 1 extension study regained about two-thirds of their lost weight within one year
US$ 20.76
US$ 21.08
US$ 24.26
US$ 26.36
US$ 26.24
US$ 20.75
